In Conjunction with His Appointment, Mr. Wambeke Purchased $750,000 of Common Shares from DiaMedica in a Private Placement Priced Above Market MINNEAPOLIS–(BUSINESS WIRE)–DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing a novel treatment for acute ischemic stroke (AIS), today announced the appointment of David Wambeke, as […]